Chapter 13 **Alpha-Synucleinopathies:** Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy

Carlos Henrique Ferreira Camargo Hospital Universitário dos Campos Gerais – UEPG, Brazil

> Marcus Vinicius Della-Coletta State University of Amazonas, Brazil

Delson José da Silva Federal University of Goias, Brazil

Hélio A. G. Teive Federal University of Paraná, Brazil

ABSTRACT

Alpha-synuclein is a protein that forms a major component of abnormal neuronal aggregates known as Lewy bodies. A particular group of neurodegenerative disorders (NDs) is characterized by the abnormal accumulation of α -synuclein; termed the α -synucleinopathies, this group includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Lysosomal storage diseases have also been linked to α -synuclein toxicity. Several therapeutic targets have been chosen among steps of metabolism of α -synuclein. Reducing α -synuclein synthesis or expression and increasing the clearance can be achieved in many ways. The development of immunotherapeutic approaches targeting α -synuclein has received considerable attention in recent years. The aim of this chapter is to present the α -synucleinopathies, as well as to present the most recent researches about treatment of synucleinopathies based on knowledge of the pathophysiology of α -synuclein pathways.

DOI: 10.4018/978-1-5225-5282-6.ch013

INTRODUCTION

A common feature among a number of neurological disorders is the abnormal aggregation of a protein as observed with amyloid beta in Alzheimer's disease (Selkoe et al., 1990) and huntingtin protein in Huntington's disease (Vonsattel et al., 2011). In 1912, Frederick Lewy first described the cytoplasmic inclusions now known as Lewy bodies in the substantia nigra in PD Cortical Lewy bodies were first reported in association with dementia in 1961 (Okazaki et al., 1961) but they were felt to be a relatively rare finding until the 1980s, when first ubiquitin and later α -synuclein immunostains made it easier to see them (Spillantini et al., 1997) and demonstrated that Lewy bodies were a common neuropathologic finding in dementia (Gomperts, 2016). α -Synucleinopathies is a particular group of NDs characterized by the abnormal accumulation of α -synuclein (Gomperts, 2016; Kahle, 2008) (Figure 1). Lysosomal storage diseases have also been linked to α -synuclein toxicity (Wong and Krainc, 2017). There are new treatments being researched based on the pathophysiology of alpha-synuclein, and immunology. The aim of this chapter is to present the α -synucleinopathies, as well as to present the most recent researches about treatment of synucleinopathies based on knowledge of the pathophysiology of α -synuclein pathways.

BACKGROUND

Despite the early knowledge of the involvement of α -synuclein in several neurodegenerative disorders, only recently has there been, as a Holy Grail, a search for the cause and cure of these diseases through α -synuclein cellular and extracellular mechanisms and pathways. A heated discussion on this topic was



Figure 1. Main common features among α -synucleinopathies

22 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

www.igi-global.com/chapter/alpha-synucleinopathies/209101

Related Content

Role of Artificial Intelligence in Modeling Psychometrics to Detect Neurodevelopmental Disorders: Use of AI to Understand Human Behavioral Aspects

Navjot Singhand Amarjot Kaur (2020). *Interdisciplinary Approaches to Altering Neurodevelopmental Disorders (pp. 213-227).*

www.irma-international.org/chapter/role-of-artificial-intelligence-in-modeling-psychometrics-to-detectneurodevelopmental-disorders/254678

The Early Diagnosis of Alzheimer's Disease: From Behavioral to Genetic Study

Yanna Ren, Weiping Yang, Xiaoyu Tang, Fengxia Wu, Satoshi Takahashiand Jinglong Wu (2021). Research Anthology on Diagnosing and Treating Neurocognitive Disorders (pp. 147-159). www.irma-international.org/chapter/the-early-diagnosis-of-alzheimers-disease/261631

Autism and Diet: An Insight Approach

Komal Srivastava (2019). *Emerging Trends in the Diagnosis and Intervention of Neurodevelopmental Disorders (pp. 194-210).*

www.irma-international.org/chapter/autism-and-diet/215171

Microglial Mitophagy and Neurodegenerative Disorders

Eyitayo Adeyemi Oyindamola, Maxwell Kwadwo Agyemang, Joseph Owusu-Sarfo, Oduro Kofi Yeboahand Newman Osafo (2020). *Quality Control of Cellular Protein in Neurodegenerative Disorders (pp. 88-128).* www.irma-international.org/chapter/microglial-mitophagy-and-neurodegenerative-disorders/250633

Alternation of Mitochondrial and Golgi Apparatus in Neurodegenerative Disorders

Sonia Sharma, Paramjeet Kaur, Shallina Guptaand Sushant Sharma (2019). *Handbook of Research on Critical Examinations of Neurodegenerative Disorders (pp. 102-128).* www.irma-international.org/chapter/alternation-of-mitochondrial-and-golgi-apparatus-in-neurodegenerativedisorders/209092